BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garderet L, D'souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P. Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. Biology of Blood and Marrow Transplantation 2017;23:1193-202. [DOI: 10.1016/j.bbmt.2017.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant 2020;26:665-71. [PMID: 31881283 DOI: 10.1016/j.bbmt.2019.12.726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
2 Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 2022. [PMID: 35523847 DOI: 10.1038/s41409-022-01697-4] [Reference Citation Analysis]
3 Iannazzo D, Ettari R, Giofrè S, Eid AH, Bitto A. Recent Advances in Nanotherapeutics for Multiple Myeloma. Cancers (Basel) 2020;12:E3144. [PMID: 33120945 DOI: 10.3390/cancers12113144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 2021;:1-12. [PMID: 34686083 DOI: 10.1080/10428194.2021.1992763] [Reference Citation Analysis]
5 Miller JJ, Taher J, Kulasingam V, Chan PC. To skim or splice? Comparing the quantification of M-proteins using two peak-integration protocols across multiple electrophoresis platforms. Clin Biochem 2022:S0009-9120(22)00021-2. [PMID: 35093313 DOI: 10.1016/j.clinbiochem.2022.01.007] [Reference Citation Analysis]
6 Abdallah HM, Zhu AZX. A Minimal Physiologically-Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug-Disease Interactions With Antibody Therapy. Clin Pharmacol Ther 2020;107:423-34. [PMID: 31449666 DOI: 10.1002/cpt.1619] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 O'Brien A, O'Halloran F, Mykytiv V. Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00316-5. [PMID: 34470720 DOI: 10.1016/j.clml.2021.07.032] [Reference Citation Analysis]
8 Settino M, Cannataro M. MMRFBiolinks: an R-package for integrating and analyzing MMRF-CoMMpass data. Brief Bioinform 2021:bbab050. [PMID: 33821961 DOI: 10.1093/bib/bbab050] [Reference Citation Analysis]